Glucocorticoids and invasive fungal infections

Lancet

Volumn 362, Issue 9398, 2003, Pages 1828-1838

  Lionakis, Michail S ^a   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE ACETATE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; METHYLPREDNISOLONE; PREDNISONE; TRANSCRIPTION FACTOR AP 1;

ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDIASIS; CLINICAL FEATURE; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CUSHING SYNDROME; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; FUNGAL DETECTION; GENE REPRESSION; HOST SUSCEPTIBILITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LYMPHOCYTE; MONOCYTE; MUCORMYCOSIS; MYCOSIS; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0344688183     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14904-5     Document Type: Review

References (135)

1. Orth D.N. Cushing's syndrome. N Engl J Med. 332:1995;791-803.
2. Graham B.S., Tucker WS Jr. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med. 101:1984;334-338.
3. O'Donnell M.R., Schmidt G.M., Tegtmeier B.R., et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol. 12:1994;827-834.
4. Morrison V.A., Haake R.J., Weisdorf D.J. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med. 96:1994;497-503.
5. Latge J.P. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 12:1999;310-350.
6. Clemons K.V., Calich V.L., Burger E., et al. Pathogenesis I: interactions of host cells and fungi. Med Mycol. 38:2000;99-111.
7. Ashman R.B., Papadimitriou J.M. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiological Reviews. Microbiol Rev. 59:1995;646-672.
8. Vasquez-Torres A., Balish E. Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev. 61:1997;170-192.
9. Lanza L., Scudeletti M., Monaco E., et al. Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. Ann N Y Acad Sci. 876:1999;193-197.
10. Fauci A.S. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. Clin Exp Immunol. 24:1976;54-62.
11. Langhoff E., Olgaard K., Ladefoged J. The immunosuppressive potency in vitro of physiological and synthetic steroids on lymphocyte cultures. Int J Immunopharmacol. 9:1987;469-473.
12. Boss B., Neeck G., Engelhardt B., Riedel W. Influence of corticosteroids on neutrophils, lymphocytes, their subsets, and T-cell activity markers in patients with active rheumatoid arthritis, compared to healthy controls. Ann N Y Acad Sci. 876:1999;198-200.
13. Balow J.E., Hurley D.L., Fauci A.S. Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity. J Immunol. 114:1975;1072-1076.
14. MacGregor R.R., Sheagren J.N., Lipsett M.B., Wolff S.M. Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med. 280:1969;1427-1431.
15. Masera R.G., Staurenghi A., Sartori M.L., Angeli A. Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome. Eur J Endocrinol. 140:1999;299-306.
16. Goulding N.J., Euzger H.S., Butt S.K., Perretti M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res. 3:1998;S158-S165.
17. Rinehart J.J., Balcerzak S.P., Sagone A.L., LoBuglio A.F. Effects of corticosteroids on human monocyte function. J Clin Invest. 54:1974;1337-1343.
18. Wurzburger M.I., Prelevic G.M., Brkic S.D., Vuckovic S., Pendic B. Cushing's syndrome - transitory immune deficiency state? Postgrad Med J. 62:1986;657-679.
19. Ohtsuka T., Kubota A., Hirano T., Watanabe K., Yoshida H., Tsurufuji M., et al. Glucocorticoid-mediated gene suppression of rat cytokine-induced neutrophil chemoattractant CINC/gro, a member of the interleukin-8 family, through impairment of NF-kappa B activation. J Biol Chem. 271:1996;1651-1659.
20. Ray K.P., Farrow S., Daly M., Talabot F., Searle N. Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids. Biochem J. 328:1997;707-715.
21. Shimoyama M., Shimmura S., Tsubota K., Oguchi Y. Suppression of nuclear factor kappa B and CD18-mediated leukocyte adhesion to the corneal endothelium by dexamethasone. Invest Ophthalmol Vis Sci. 38:1997;2427-2431.
22. Dandona P., Aljada A., Ghanim H., Mohanty P., Hamouda W., Al-Haddad W. Acute suppressive effect of hydrocortisone on p47 subunit of nicotinamide adenine dinucleotide phosphate oxidase. Metabolism. 50:2001;548-552.
23. Ray A., Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA. 91:1994;752-756.
24. Mukaida N., Morita M., Ishikawa Y., et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8-gene repression. J Biol Chem. 269:1994;13289-13295.
25. Gudewicz P.W. The effects of cortisone therapy on lung macrophage host defense function and glucose metabolism. Circ Shock. 8:1981;95-103.
26. Duong M., Aouellet N., Simard M., Bergeron Y., Olivier M., Bergeron M.G. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis. 178:1998;1472-1482.
27. Strozik K.S., Schoeman J.F., Pieper C.H., Donald P.R. The effect of short-term prednisone therapy on the Mantoux skin test. Pediatr Infect Dis J. 17:1998;658-660.
28. Cenci E., Perito S., Enssle K.H., et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun. 65:1997;564-570.
29. Almawi W.Y., Melemedjian O.K., Rieder M.J. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant. 13:1999;365-374.
30. Kovalovsky D., Refojo D., Holsboer F., Arzt E. Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol. 109:2000;23-29.
31. Liles W.C., Dale D.C., Klebanoff S.J. Glucocorticoids inhibit apoptosis of human neutrophils. Blood. 86:1995;3181-3188.
32. Amsterdam A., Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol. 189:2002;1-9.
33. Roilides E., Uhlig K., Venzon D., Pizzo P.A., Walsh T.J. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun. 61:1993;4870-4877.
34. Diamond R.D. Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J Infect Dis. 147:1983;2160.
35. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest. 76:1985;1755-1764.
36. Kleinert H., Euchenhofer C., Ihrig-Biedert I., Forstermann U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B. Mol Pharmacol. 49:1996;15-21.
37. Brummer E., Maqbool A., Stevens D.A. Protection of bronchoalveolar macrophages by granulocyte-macrophage colony-stimulating factor (GM-CSF) against dexamethasone suppression of fungicidal activity for Aspergillus fumigatus conidia. Med Mycol. 39:2001;509-515.
38. Brummer E., Kamberi M., Stevens D.A. Regulation by Granulocyte- macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. 187:2003;705-709.
39. Moser M., De Smedt T., Sornasse T., et al. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur J Immunol. 25:1995;2818-2824.
40. Aberer W., Stingl L., Pogantsch S., Stingl G. Effect of glucocorticosteroids on epidermal cell-induced immune responses. J Immunol. 133:1984;792-797.
41. Chang J.Y., Liu L.Z. Inhibition of microglial nitric oxide production by hydrocortisone and glucocorticoid precursors. Neuro Res. 25:2000;903-908.
42. Hardman J.G., Gilman A.G., Limbard L.E. Goodman and Gilman's the pharmacological basis of therapeutics. 10th edn: 2001; McGraw-Hill Companies.
43. DeRijk R.H., Schaaf M., de Kloet E.R. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol. 81:2002;103-122.
44. Huizenga N.A., Koper J.W., De Lange P., et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab. 83:1998;144-151.
45. Bakker R.C., Gallas P.R., Romijn J.A., Wiersinga W.M. Cushing's syndrome complicated by multiple opportunistic infections. J Endo Invest. 21:1998;329-333.
46. Dimopoulos M.A., Fernandez J.F., Samaan N.A., Holoye P.Y., Vassilopoulou-Sellin R. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer. 69:1992;66-71.
47. Findling J.W., Tyrrell J.B., Aron D.C., Fitzgerald P.A., Young C.W., Sohnle P.G. Fungal infections in Cushing's syndrome. Ann Intern Med. 95:1981;2392.
48. Sarlis N.J., Chanock S.J., Nieman L.K. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 85:2000;42-47.
49. Peter E., Bakri F., Ball D.M., Cheney R.T., Segal B.H. Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis. 35:2002;54-56.
50. Leav B.A., Fanburg B., Hadley S. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med. 343:2000;586.
51. Wald A., Leisenring W., van Burik J.A., Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 175:1997;1459-1466.
52. Ribaud P., Chastang C., Latge J.P., et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 28:1999;322-330.
53. Hovi L., Saarinen-Pihkala U.M., Vettenranta K., Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 26:2000;999-1004.
54. Gustafson T.L., Schaffner W., Lavely G.B., Stratton C.W., Johnson H.K., Hutcheson RH Jr. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis. 148:1983;230-238.
55. Marr K.A., Carter R.A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 100:2002;4358-4366.
56. Bell M.J., Martin L.W., Gonzales L.L., McEnery P.T., West C.D. Alternate-day single-dose prednisone therapy: a method of reducing steroid toxicity. J Pediatr Surg. 7:1972;223-229.
57. Dale D.C., Fauci A.S., Wolff S.M. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med. 291:1974;1154-1158.
58. Vincenti F., Amend W., Feduska N.J., Duca R.M., Salvatierra O Jr. Improved outcome following renal transplantation with reduction in the immunosuppression therapy for rejection episodes. Am J Med. 69:1980;107-112.
59. Cohen D.J., Loertscher R., Rubin M.F., Tilney N.L., Carpenter C.B., Strom T.B. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med. 101:1984;667-682.
60. Ferguson R.M., Sommer B.G. Cyclosporine in renal transplantation: a single institutional experience. Am J Kidney Dis. 5:1985;296-306.
61. Klein N.C., Go Ch, Cunha B.A. Infections associated with steroid use. Infect Dis Clin North Am. 15:2001;423-432.
62. O' Day D.M., Ray W.A., Robinson R., Head W.S. Efficacy of antifungal agents in the cornea. II. Influence of corticosteroids. Invest Ophthalmol Vis Sci. 25:1984;331-335.
63. Graybill J.R., Bocanegra R., Najvar L.K., Loebenberg D., Luther M.F. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. J Antimicrob Chemother. 42:1998;2467-2473.
64. Menzel F Jr, Jackson C, Patera A, et al. Combination treatment of posaconazole and granulocyte-stimulating factor (G-CSF) against Aspergillus in a mouse pulmonary infection mouse. Abstract in 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2002, San Diego, California: M-858.
65. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma (in press).
66. Nucci M., Anaissie E., Queiroz-Telles, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 98:2003;315-319.
67. Ng T.T., Robson G.D., Denning D.W. Hydrocortisone-enhanced growth of Aspergillus spp: implications for pathogenesis. Microbiology. 140:1994;2475-2479.
68. Kontoyiannis D.P., Bodey G.P. Invasive aspergillosis in 2002: an update. Euro J Clin Microb Infect Dis. 21:2002;161-172.
69. Denning D.W. Invasive aspergillosis. Clin Infect Dis. 26:1998;781-803.
70. Berenguer J., Allende M.C., Lee J.W., et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone- induced immunosupression. Am J Respir Crit Care Med. 152:1995;1079-1086.
71. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 34:2002;909-917.
72. Grow W.B., Moreb J.S., Roque D., et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 29:2002;15-19.
73. Martino R., Subira M., Rovira M., et al. AlloPBSCT Infectious/non- infectious complications subcommittees of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 116:2002;475-482.
74. Jantunen E., Ruutu P., Niskanen L., et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 19:1997;801-888.
75. Wajszczuk C.P., Dummer J.S., Ho M., et al. Fungal infections in liver transplant recipients. Transplantation. 40:1985;347-353.
76. Ruffini E., Baldi S., Rapellino M., et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;181-190.
77. Patterson J.E. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1:1999;229-236.
78. Iriya S.M., Capelozzi V.L., Calich I., Martins M.A., Lichtenstein A. Causes of death in patients with systemic lupus erythematosus in São Paulo, Brazil: a study of 113 autopsies. Arch Intern Med. 161:2001;1557.
79. Lortholary O., Ascioglu S., Moreau P., et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. Clin Infect Dis. 30:2000;41-46.
80. Khoo S.H., Denning D.W. Invasive aspergillosis in patients with AIDS. Clin Infect Dis. 1:1994;41-48.
81. Fairfax A.J., David V., Douce G. Laryngeal aspergillosis following high dose inhaled fluticasone therapy for asthma. Thorax. 54:1999;860-861.
82. Kleinschmidt-DeMasters B.K. Central nervous system aspergillosis: a 20-year retrospective series. Human Path. 33:2002;116-124.
83. Kontoyiannis D.P., Wessel V.C., Bodey G.P., Rolston K.V. Zygomycosis in the in a tertiary-care cancer center. Clin Infect Dis; 30. 2000:1990s;851-856.
84. Jimenez C., Lumbreras C., Aguado J.M., et al. Successful treatment of Mucor infection after liver or pancreas-kidney transplantation. Transplant. 73:2002;476-480.
85. Walsh T.J., Groll A.H. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 1:1999;247-261.
86. Ponton J., Ruchel R., Clemons K.V., et al. Emerging pathogens. Med Mycol. 38:2000;225-236.
87. Sampathkumar P., Paya C.V. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 32:2001;1237-1240.
88. Rossmann S.N., Cernoch P.L., Davis J.R. Dematiaceous fungi are an increasing cause of human disease. Clin Infect Dis. 22:1996;73-80.
89. Baddley J.W., Stroud T.P., Salzman D., Pappas P.G. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 32:2001;1319-1324.
90. Heidenreich S., Kubis T., Schmidt M., Fegeler W. Glucocorticoid-induced alterations of monocyte defense mechanisms against Candida albicans. Cell Immunol. 157:1994;320-327.
91. Bykov V.L. Morphological analysis of the effect of corticosteroids on the development and course of vaginal candidiasis. Akush Ginekol. 2:1989;35-37.
92. Maraki S., Hajiioannou I., Anatoliotakis N., et al. Ceftriaxone and dexamethasone affecting yeast gut flora in experimental mice. J Chem. 11:1999;363-366.
93. Myerowitz R.L. Gastrointestinal and disseminated candidiasis. An experimental model in the immunosuppressed rat. Arch Pathol Lab Med. 105:1981;138-143.
94. Loose D.S., Schurman D.J., Feldman D. A corticosteroid binding protein and endogenous ligand in C albicans indicating a possible steroid-receptor system. Nature. 293:1981;477-479.
95. Nucci M., Colombo A.L. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis. 21:2002;209-211.
96. Kontoyiannis D.P., Vaziri I., Hanna H.A., et al. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis. 33:2001;1676-1681.
97. Gumbo T., Isada C.M., Hall G., Karafa M.T., Gordon S.M. Candida glabrata Fungemia. Clinical features of 139 patients. Medicine. 78:1999;220-227.
98. Krcmery V Jr, Mrazova M., Kunova A., et al. Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer. 7:1999;428-431.
99. Bodey G.P., Mardani M., Hanna H.A., et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 112:2002;380-385.
100. Kontoyiannis D.P., Reddy B.T., Hanna H., Bodey G.P., Tarrand J., Raad I.I. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 23:2002;542-545.
101. Naef M., von Overbeck J., Seiler C., Baer H.U. Candida infection in surgery. Chirurg. 65:1994;785-790.
102. Sung J.M., Ko W.C., Huang J.J. Candidaemia in patients with dialysis-dependent acute renal failure: aetiology, predisposing and prognostic factors. Nephrol Dial Transplant. 16:2001;2348-2356.
103. Hellmann D.B., Petri M., Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine. 66:1987;341-348.
104. Botas C.M., Kurlat I., Young S.M., Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics. 95:1995;883-887.
105. Nieto-Rodriguez J.A., Kusne S., Manez R., et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg. 223:1996;70-76.
106. Sepkowitz K.A. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis. 34:2002;1098-1107.
107. Perfect J.R., Durack D.T., Gallis H.A. Cryptococcemia. Medicine. 62:1983;98-109.
108. Dromer F., Mathoulin S., Dupont B., Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey. French Cryptococcosis Study Group. Clin Infect Dis; 23. 1996:1985;82-90.
109. Dromer F., Mathoulin S., Dupont B., Letenneur L., Ronin O. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis. 3:1996;91-96.
110. Gross N.T., Chinchilla M., Camner P., Jarstrand C. Anticryptococcal activity by alveolar macrophages from rats treated with cortisone acetate during different periods of time. Mycopathologia. 136:1996;1-8.
111. Kontoyiannis D.P., Peitsch W.K., Reddy B.T., et al. Cryptococcosis in patients with cancer. Clin Infect Dis. 32:2001;E145-E150.
112. Liu P.Y. Cryptococcal osteomyelitis: case report and review. Diagn Microbiol Infect Dis. 30:1998;33-35.
113. Perfect J.R., Durack D.T. Chemotactic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Sabouraudia. 23:1985;37-45.
114. Diamond R.D., Bennett J.E. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 80:1974;176-181.
115. Chagua MR, Hachem R, Raad I, Kontoyiannis DP. Trichosporonosis in a Tertiary Care Cancer Center: Risk Factors, Spectrum and Determinants of Outcome. 40th Annual Meeting of The Infectious Diseases Society of America (IDSA) 2002, Chicago, Illinois: 100859.
116. Sepkowitz K.A., Brown A.E., Telzak E.E., Gottlieb S., Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 267:1992;832-837.
117. Ognibene F.P., Shelhamer J.H., Hoffman G.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 151:1995;795-799.
118. Godeau B., Coutant-Perronne V., Le Thi Huong D., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 21:1994;246-251.
119. Hayes M.J., Torzillo P.J., Sheil A.G., McCaughan G.W. Pneumocystis carinii pneumonia after liver transplantation in adults. Clin Transpl. 8:1994;499-503.
120. Slivka A., Wen P.Y., Shea W.M., Loeffler J.S. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 94:1993;216-219.
121. Henson J.W., Jalaj J.K., Walker R.W., Stover D.E., Fels A. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol. 48:1991;406-409.
122. Walzer P.D., Powell RD Jr, Yoneda K., Rutledge M.E., Milder J.E. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect Immun. 27:1980;928-937.
123. Anaissie E.J., Kontoyiannis D.P., O'Brien S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 129:1998;559-566.
124. Lyytikainen O., Ruutu T., Volin L., et al. Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 17:1996;1057-1059.
125. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clinic Proceedings. 71:1996;5-13.
126. Porges A.J., Beattie S.L., Ritchlin C., Kimberly R.P., Christian C.L. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol. 19:1992;1191-1214.
127. Abernathy-Carver K.J., Fan L.L., Boguniewicz M., Larsen G.L., Leung D.Y. Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol. 18:1994;135-138.
128. Hartel B., Knoch M., Muller E., Mutters R., Lennartz H. The importance of Pneumocystis carinii infection in patients with acute respiratory distress syndrome. Anasth Intensiv Notfallmed Schmerzther. 26:1991;102-104.
129. Dismukes W.E., Royal S.A., Tynes B.S. Disseminated histoplasmosis in corticosteroid-treated patients. Report of five cases. JAMA. 240:1978;1495-1498.
130. Hansen K.E., St Clair E.W. Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature. Semin Arthritis Rheum. 28:1998;193-199.
131. Torres H.A., Rivero G.A., Kontoyiannis D.P. Endemic mycoses in a cancer hospital. Medicine. 81:2002;201-212.
132. Goodman D.H. Systemic fungal infection complications in asthmatic patients treated with steroids. Ann Allergy. 31:1973;205-208.
133. Johnson W.M., Gall E.P. Fatal coccidioidomycosis in collagen vascular diseases. J Rheumatol. 10:1983;79-84.
134. Recht L.D., Davies S.F., Eckman M.R., Sarosi G.A. Blastomycosis in immunosuppressed patients. Am Rev Respir Dis. 125:1982;359-362.
135. Carrada-Bravo T. New observations on the epidemiology and pathogenesis of sporotrichosis. Ann Trop Med Parasitol. 69:1975;267-273.